Ionis’s inhaled antisense candidate shows promising signs, with Arrowhead and Translate Bio also in the running.
Global drug stocks enthusiastically joined the recovery on the financial markets in the second quarter, more than offsetting earlier declines.
Behind Global Blood and Novartis, Bluebird leads a pack of biotechs wanting a slice of the sickle cell disease market.
The plan to file Lentiglobin for sickle cell disease next year gets the green light, as a patient death is deemed unrelated to treatment.
Keytruda sales could be more than double any other product in 2026, new estimates suggests, as Merck’s cancer drug surges into the record books.
A clutch of swift FDA decisions boosted average US drug approval times in 2019, helping biopharma to deliver another bumper crop of new medicines.